Distinct and redundant functions of histone deacetylases HDAC1 and HDAC2 in proliferation and tumorigenesis

Cell Cycle

Volumn 10, Issue 3, 2011, Pages 406-412

  Jurkin, Jennifer ^a,c   Zupkovitz, Gordin ^a   Lagger, Sabine ^a   Grausenburger, Reinhard ^a,d   Hagelkruys, Astrid ^a   Kenner, Lukas ^b   Seiser, Christian ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

Author keywords

Chromatin; Epigenetics; HDAC inhibitor; Histone acetylation; Proliferation; Teratoma; Tumor therapy; Tumorigenesis

Indexed keywords

BETA ACTIN; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2;

APOPTOSIS; CANCER GROWTH; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TYPE; GENE EXPRESSION; HUMAN; PROTEIN FAMILY; REVIEW; TERATOMA; TUMOR MODEL;

EID: 79851477462     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.3.14712     Document Type: Review

References (38)

1. Yang XJ, Seto E. Lysine acetylation: codified cross-talk with other posttranslational modifications. Mol Cell 2008; 31:449-61.
2. Brandl A, Heinzel T, Kramer OH. Histone deacetylases: salesmen and customers in the post-translational modification market. Biology of the cell/under the auspices of the European Cell Biology Organization 2009; 101:193-205.
3. Nakagawa M, Oda Y, Eguchi T, Aishima S, Yao T, Hosoi F, et al. Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep 2007; 18:769-74.
4. Warrener R, Beamish H, Burgess A, Waterhouse NJ, Giles N, Fairlie D, et al. Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints. Faseb J 2003; 17:1550-2.
5. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003; 370:737-49. (Pubitemid 36399066)
6. Bertrand P. Inside HDAC with HDAC inhibitors. European journal of medicinal chemistry 2010; 45:2095-116.
7. Khier H, Bartl S, Schuettengruber B, Seiser C. Molecular cloning and characterization of the mouse histone deacetylase 1 gene: integration of a retrovirus in 129SV mice. Biochim Biophys Acta 1999; 1489:365-73.
8. Brunmeir R, Lagger S, Seiser C. Histone deacetylase HDAC1/HDAC2- controlled embryonic development and cell differentiation. Int J Dev Biol 2009; 53:275-89.
9. Lagger G, O'Carroll D, Rembold M, Khier H, Tischler J, Weitzer G, et al. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J 2002; 21:2672-81. (Pubitemid 34619383)
10. Senese S, Zaragoza K, Minardi S, Muradore I, Ronzoni S, Passafaro A, et al. Role for histone deacetylase 1 in human tumor cell proliferation. Mol Cell Biol 2007; 27:4784-95. (Pubitemid 47016131)
11. Zimmermann S, Kiefer F, Prudenziati M, Spiller C, Hansen J, Floss T, et al. Reduced body size and decreased intestinal tumor rates in HDAC2-mutant mice. Cancer Res 2007; 67:9047-54. (Pubitemid 47535889)
12. 1-to-S progression. Genes Dev 2010; 24:455-69.
13. Grausenburger R, Bilic I, Boucheron N, Zupkovitz G, El-Housseiny L, Tschismarov R, et al. Conditional deletion of histone deacetylase 1 in T cells leads to enhanced airway inflammation and increased Th2 cytokine production. J Immunol 2010; 185:3489-97.
14. Lagger S, Meunier D, Mikula M, Brunmeir R, Schlederer M, Artaker M, et al. Crucial function of histone deacetylase 1 for differentiation of teratomas in mice and humans. EMBO J 2010; 29:3992-4007.
15. Wilting RH, Yanover E, Heideman MR, Jacobs H, Horner J, van der Torre J, et al. Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis. EMBO J 2010; 29:2586-97.
16. Schuettengruber B, Simboeck E, Khier H, Seiser C. Autoregulation of mouse histone deacetylase 1 expression. Mol Cell Biol 2003; 23:6993-7004. (Pubitemid 37214666)
17. Dovey OM, Foster CT, Cowley SM. Histone deacetylase 1 (HDAC1), but not HDAC2, controls embryonic stem cell differentiation. Proc Natl Acad Sci USA 2010; 107:8242-7.
18. Bartl S, Taplick J, Lagger G, Khier H, Kuchler K, Seiser C. Identification of mouse histone deacetylase 1 as a growth factor-inducible gene. Mol Cell Biol 1997; 17:5033-43. (Pubitemid 27357602)
19. Zupkovitz G, Grausenburger R, Brunmeir R, Senese S, Tischler J, Jurkin J, et al. The cyclin-dependent kinase inhibitor p21 is a crucial target for histone deacetylase 1 as a regulator of cellular proliferation. Mol Cell Biol 30:1171-81.
20. Glaser KB, Li J, Staver MJ, Wei RQ, Albert DH, Davidsen SK. Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem Biophys Res Commun 2003; 310:529-36. (Pubitemid 37163696)
21. Oh M, Choi IK, Kwon HJ. Inhibition of histone deacetylase1 induces autophagy. Biochem Biophys Res Commun 2008; 369:1179-83.
22. Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ 2005; 12:395-404.
23. Harms KL, Chen X. Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity. Cancer Res 2007; 67:3145-52. (Pubitemid 46724851)
24. Bicaku E, Marchion DC, Schmitt ML, Munster PN. Selective inhibition of histone deacetylase 2 silences progesterone receptor-mediated signaling. Cancer Res 2008; 68:1513-9. (Pubitemid 351346860)
25. Marchion DC, Bicaku E, Turner JG, Schmitt ML, Morelli DR, Munster PN. HDAC2 regulates chromatin plasticity and enhances DNA vulnerability. Mol Cancer Ther 2009; 8:794-801.
26. Fritsche P, Seidler B, Schuler S, Schnieke A, Gottlicher M, Schmid RM, et al. HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA. Gut 2009; 58:1399-409.
27. Khabele D, Son DS, Parl AK, Goldberg GL, Augenlicht LH, Mariadason JM, Rice VM. Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy. Cancer Biol Ther 2007; 6:795-801. (Pubitemid 47328364)
28. Inoue S, Mai A, Dyer MJ, Cohen GM. Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 2006; 66:6785-92. (Pubitemid 44085638)
29. Weichert W, Roske A, Niesporek S, Noske A, Buckendahl AC, Dietel M, et al. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res 2008; 14:1669-77. (Pubitemid 351469450)
30. Montgomery RL, Davis CA, Potthoff MJ, Haberland M, Fielitz J, Qi X, et al. Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev 2007; 21:1790-802. (Pubitemid 47076478)
31. Ye F, Chen Y, Hoang T, Montgomery RL, Zhao XH, Bu H, et al. HDAC1 and HDAC2 regulate oligodendrocyte differentiation by disrupting the beta-catenin-TCF interaction. Nat Neurosci 2009; 12:829-38.
32. Montgomery RL, Hsieh J, Barbosa AC, Richardson JA, Olson EN. Histone deacetylases 1 and 2 control the progression of neural precursors to neurons during brain development. Proc Natl Acad Sci USA 2009; 106:7876-81.
33. Haberland M, Johnson A, Mokalled MH, Montgomery RL, Olson EN. Genetic dissection of histone deacetylase requirement in tumor cells. Proc Natl Acad Sci USA 2009; 106:7751-5.
34. Magnaghi-Jaulin L, Groisman R, Naguibneva I, Robin P, Lorain S, Le Villain JP, et al. Retinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature 1998; 391:601-5. (Pubitemid 28157604)
35. Prince HM, Bishton MJ, Harrison SJ. Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 2009; 15:3958-69.
36. Kramer OH, Zhu P, Ostendorff HP, Golebiewski M, Tiefenbach J, Peters MA, et al. The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J 2003; 22:3411-20. (Pubitemid 36834871)
37. Ropero S, Fraga MF, Ballestar E, Hamelin R, Yamamoto H, Boix-Chornet M, et al. A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat Genet 2006; 38:566-9.
38. Mercurio C, Minucci S, Pelicci PG. Histone deacetylases and epigenetic therapies of hematological malignancies. Pharmacol Res 2010; 62:18-34.